A study examining donor-recipient pairs decades after hematopoietic cell transplantation finds no significant accelerated ...

T cells and allogeneic hematopoietic stem cell transplantation. Dr Simonetta's clinical work is mainly focused on Chimeric ...

Patients with relapsed or refractory MDS may experience improved overall survival with , depending on certain prognostic ...

Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but ...

The BLA approval is supported by data from the COBLT study, FDA dockets and public information, and from a RegeneCyte observational database.

The following is a summary of “Association between early anti-cytomegalovirus therapy and the incidence of chronic ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has had no related adverse events to date.

The risk for COVID-19 hospitalization is low in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), ...

Omeros ( OMER, Financials) announced progress toward resubmitting its biologics license application for narsoplimab, its ...

Opens in a new tab or window While high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT ...

SEATTLE--Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its ...